BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32298429)

  • 1. Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA.
    Rutherford SC; Herold M; Hiddemann W; Kostakoglu L; Marcus R; Martelli M; Sehn LH; Trněný M; Trotman J; Vitolo U; Nielsen T; Mattiello F; Sahin D; Sellam G; Martin P
    Blood Adv; 2020 Apr; 4(8):1589-1593. PubMed ID: 32298429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
    Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
    Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials.
    Kostakoglu L; Martelli M; Sehn LH; Davies A; Trněný M; Herold M; Vitolo U; Hiddemann W; Trotman J; Knapp A; Mattiello F; Nielsen TG; Sahin D; Sellam G; Ward C; Younes A
    EJHaem; 2023 Nov; 4(4):1042-1051. PubMed ID: 38024624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study.
    Alzahrani M; El-Galaly TC; Hutchings M; Hansen JW; Loft A; Johnsen HE; Iyer V; Wilson D; Sehn LH; Savage KJ; Connors JM; Gascoyne RD; Johansen P; Clasen-Linde E; Brown P; Villa D
    Ann Oncol; 2016 Jun; 27(6):1095-1099. PubMed ID: 27002106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma.
    St-Pierre F; Broski SM; LaPlant BR; Maurer MJ; Ristow K; Thanarajasingam G; Macon WR; Habermann TM; Witzig TE
    Oncologist; 2020 Aug; 25(8):689-695. PubMed ID: 32319706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.
    Klanova M; Oestergaard MZ; Trněný M; Hiddemann W; Marcus R; Sehn LH; Vitolo U; Bazeos A; Goede V; Zeuner H; Knapp A; Sahin D; Spielewoy N; Bolen CR; Cardona A; Klein C; Venstrom JM; Nielsen T; Fingerle-Rowson G
    Clin Cancer Res; 2019 Aug; 25(15):4634-4643. PubMed ID: 31053601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of Positron Emission Tomography-Computed Tomography and Bone Marrow Biopsy in Detecting Bone Marrow Infiltration in Lymphoma Cases.
    Büyükşimşek M; Kolsuz İ; Yetişir AE; Tohumcuoğlu M; Oğul A; Mirili C; Paydaş S; Güney İB
    Turk J Haematol; 2020 Nov; 37(4):220-225. PubMed ID: 32003552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of visual and quantitative bone marrow FDG-PET/CT findings with bone marrow biopsy results in diffuse large B-cell lymphoma: does bone marrow FDG-PET/CT live up to its promise?
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Acta Radiol; 2015 Oct; 56(10):1230-5. PubMed ID: 25387723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma.
    Hong J; Lee Y; Park Y; Kim SG; Hwang KH; Park SH; Jeong J; Kim KH; Ahn JY; Park S; Park J; Lee JH
    Ann Hematol; 2012 May; 91(5):687-695. PubMed ID: 22008868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
    Sehn LH; Martelli M; Trněný M; Liu W; Bolen CR; Knapp A; Sahin D; Sellam G; Vitolo U
    J Hematol Oncol; 2020 Jun; 13(1):71. PubMed ID: 32505213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow evaluation in initial staging of lymphoma: 18F-FDG PET/CT versus bone marrow biopsy.
    Cortés-Romera M; Sabaté-Llobera A; Mercadal-Vilchez S; Climent-Esteller F; Serrano-Maestro A; Gámez-Cenzano C; González-Barca E
    Clin Nucl Med; 2014 Jan; 39(1):e46-52. PubMed ID: 23640215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of bone marrow 2-[
    Lim CH; Hyun SH; Cho YS; Choi JY; Lee KH
    Clin Radiol; 2021 Jul; 76(7):550.e19-550.e28. PubMed ID: 33762136
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow biopsy can be omitted in the diagnostic workup of CNS lymphoma of DLBCL origin: a population-based retrospective study in the PET-CT era.
    Jelicic J; Hansen DL; Carlsen SS; Thorsgaard M; Hersby DS; Kannik K; Munksgaard ASE; Larsen TS; Juul-Jensen K
    Ann Hematol; 2023 Jul; 102(7):1897-1905. PubMed ID: 37246974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopsy remains indispensable for evaluating bone marrow involvement in DLBCL patients despite the use of positron emission tomography.
    Saiki Y; Tomita N; Uchida A; Uemura Y; Suzuki Y; Hirakawa T; Kato M; Hoshikawa M; Kawano T; Nakamura N; Miura I; Arai A
    Int J Hematol; 2021 May; 113(5):675-681. PubMed ID: 33515158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.
    Strefford JC; Nowicka M; Hargreaves CE; Burton C; Davies A; Ganderton R; Hiddemann W; Iriyama C; Klapper W; Latham KV; Martelli M; Mir F; Parker H; Potter KN; Rose-Zerilli MJJ; Sehn LH; Trněný M; Vitolo U; Bolen CR; Klein C; Knapp A; Oestergaard MZ; Cragg MS
    Blood Adv; 2021 Aug; 5(15):2935-2944. PubMed ID: 34323957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.